Intech Investment Management LLC Purchases 8,183 Shares of Eli Lilly and Company (NYSE:LLY)

Intech Investment Management LLC grew its position in Eli Lilly and Company (NYSE:LLY) by 4.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 182,351 shares of the company’s stock after buying an additional 8,183 shares during the period. Eli Lilly and Company accounts for approximately 1.5% of Intech Investment Management LLC’s investment portfolio, making the stock its 8th largest holding. Intech Investment Management LLC’s holdings in Eli Lilly and Company were worth $106,296,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Eli Lilly and Company by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after purchasing an additional 659,838 shares during the period. Morgan Stanley raised its holdings in Eli Lilly and Company by 0.7% during the 3rd quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock worth $6,738,605,000 after buying an additional 83,915 shares during the period. Norges Bank bought a new position in Eli Lilly and Company in the fourth quarter valued at approximately $5,992,890,000. Northern Trust Corp boosted its holdings in shares of Eli Lilly and Company by 3.6% in the third quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock valued at $5,456,314,000 after buying an additional 355,317 shares during the period. Finally, International Assets Investment Management LLC increased its position in shares of Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after acquiring an additional 7,330,815 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of LLY traded down $1.02 during trading hours on Friday, hitting $807.43. 1,778,120 shares of the company were exchanged, compared to its average volume of 2,894,329. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a fifty-two week low of $419.80 and a fifty-two week high of $820.60. The company has a market cap of $767.39 billion, a price-to-earnings ratio of 118.91, a P/E/G ratio of 1.76 and a beta of 0.37. The firm’s fifty day moving average is $765.47 and its 200 day moving average is $692.97.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the prior year, the company posted $1.62 earnings per share. The business’s revenue for the quarter was up 26.0% on a year-over-year basis. On average, equities analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.64%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on LLY. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. Argus upped their price target on Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Barclays lifted their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price target (up from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday, April 30th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $769.53.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.